Self-Treat Vagus Nerve Stimulator Shows Promise For Cluster Headaches
This article was originally published in The Gray Sheet
Executive Summary
A one-year open-label study published in Neurology suggests that electroCore’s gammaCore non-invasive vagus nerve stimulation system could be a practical therapy for chronic cluster headaches.
You may also be interested in...
ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache
Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.